Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 24, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share ownership changes rather than a financial performance report.
Material Changes
The filing details changes in the number of Ordinary Share American Depositary Receipts (ADRs) held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan"):
- March 16, 2006: Holdings decreased from 17,734,613 to 17,624,275 ADRs at an average price of $54.40.
- March 23, 2006: Holdings decreased from 17,624,275 to 17,561,959 ADRs at an average price of $54.52.
Management Commentary and Risks
The Plan is a discretionary fund where all employees or former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. Two directors, Dr. J.P. Garnier and Dr. T. Yamada, are noted as potentially interested in the shares held in the fund in the same manner as other employees. The notification complies with Disclosure Rule 3.1.4 R(1)(b).
Investor Verification Points
- Verify the total aggregate holdings of the US Retirement Savings Plan to assess the scale of the reported reductions.
- Confirm the specific nature of the "movement in the fund" (e.g., rebalancing, withdrawals, or market adjustments) that triggered these transactions.
- Review subsequent filings to determine if the trend of decreasing holdings in the Plan continued.